{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:44:01Z","timestamp":1785329041705,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T00:00:00Z","timestamp":1518220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T00:00:00Z","timestamp":1518220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2019,6,15]]},"DOI":"10.1007\/s12029-018-0073-8","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T23:44:36Z","timestamp":1518219876000},"page":"285-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence"],"prefix":"10.1007","volume":"50","author":[{"given":"Margaret D.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah L.","family":"Deneve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton V.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Behrman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Glazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,10]]},"reference":[{"issue":"1","key":"73_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21332.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"73_CR2","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-15-0426","volume":"21","author":"LA Chantrill","year":"2015","unstructured":"Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, et al. Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clin Cancer Res. 2015;21(9):2029\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0426.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"73_CR3","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3748\/wjg.v23.i10.1872","volume":"23","author":"H Oweira","year":"2017","unstructured":"Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a surveillance epidemiology and end results database analysis. World J Gastroenterol. 2017;23(10):1872\u201380. https:\/\/doi.org\/10.3748\/wjg.v23.i10.1872.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"73_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.pan.2016.03.016","volume":"16","author":"S Kruger","year":"2016","unstructured":"Kruger S, Haas M, Burger PJ, Ormanns S, Modest DP, Westphalen CB, et al. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology. 2016;16(4):593\u20138. https:\/\/doi.org\/10.1016\/j.pan.2016.03.016.","journal-title":"Pancreatology"},{"issue":"4","key":"73_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500\u20133. https:\/\/doi.org\/10.1038\/nm.2344.","journal-title":"Nat Med"},{"issue":"7592","key":"73_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47\u201352. https:\/\/doi.org\/10.1038\/nature16965.","journal-title":"Nature"},{"issue":"364","key":"73_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag2306","volume":"8","author":"TJ Goodwin","year":"2016","unstructured":"Goodwin TJ, Zhou Y, Musetti SN, Liu R, Huang L. Local and transient gene expression primes the liver to resist cancer metastasis. Sci Transl Med. 2016;8(364):364ra153. https:\/\/doi.org\/10.1126\/scitranslmed.aag2306.","journal-title":"Sci Transl Med"},{"key":"73_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1055-3207(18)30064-4","volume":"10","author":"IJ Fidler","year":"2001","unstructured":"Fidler IJ. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am. 2001;10:257\u201369. vii-viiii","journal-title":"Surg Oncol Clin N Am"},{"issue":"3","key":"73_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccell.2017.02.014","volume":"31","author":"EA Collisson","year":"2017","unstructured":"Collisson EA, Maitra A. Pancreatic cancer genomics 2.0: profiling metastases. Cancer Cell. 2017;31(3):309\u201310. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.014.","journal-title":"Cancer Cell"},{"issue":"3","key":"73_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3753","volume":"49","author":"OG McDonald","year":"2017","unstructured":"McDonald OG, Li X, Saunders T, et al. Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet. 2017;49(3):367\u201376. https:\/\/doi.org\/10.1038\/ng.3753.","journal-title":"Nat Genet"},{"issue":"1","key":"73_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13048-016-0259-2","volume":"9","author":"G Yaghmour","year":"2016","unstructured":"Yaghmour G, Prouet P, Wiedower E, Jamy OH, Feldman R, Chandler JC, et al. Genomic alterations in neuroendocrine cancers of the ovary. J Ovarian Res. 2016;9(1):52. https:\/\/doi.org\/10.1186\/s13048-016-0259-2.","journal-title":"J Ovarian Res"},{"issue":"8","key":"73_CR12","first-page":"4033","volume":"36","author":"G Yaghmour","year":"2016","unstructured":"Yaghmour G, Pandey M, Ireland C, Patel K, Nunnery S, Powell D, et al. Role of genomic instability in immunotherapy with checkpoint inhibitors. Anticancer Res. 2016;36(8):4033\u20138.","journal-title":"Anticancer Res"},{"issue":"1","key":"73_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10549-016-3867-z","volume":"158","author":"B McCullar","year":"2016","unstructured":"McCullar B, Pandey M, Yaghmour G, Hare F, Patel K, Stein M, et al. Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. Breast Cancer Res Treat. 2016;158(1):195\u2013202. https:\/\/doi.org\/10.1007\/s10549-016-3867-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"73_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/ng.3764","volume":"49","author":"AP Makohon-Moore","year":"2017","unstructured":"Makohon-Moore AP, Zhang M, Reiter JG, Bozic I, Allen B, Kundu D, et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet. 2017;49(3):358\u201366. https:\/\/doi.org\/10.1038\/ng.3764.","journal-title":"Nat Genet"},{"issue":"10","key":"73_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.6004\/jnccn.2015.0147","volume":"13","author":"AW Hahn","year":"2015","unstructured":"Hahn AW, Giri S, Patel D, Sluder H, Vanderwalde A, Martin MG. Next-generation sequencing and in silico analysis facilitate prolonged response to pazopanib in a patient with metastatic urothelial carcinoma of the renal pelvis. J Natl Compr Cancer Netw. 2015;13(10):1181\u20135. https:\/\/doi.org\/10.6004\/jnccn.2015.0147.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"7540","key":"73_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495\u2013501. https:\/\/doi.org\/10.1038\/nature14169.","journal-title":"Nature"},{"issue":"2-3","key":"73_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.mrrev.2008.12.001","volume":"681","author":"S Landi","year":"2009","unstructured":"Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: a review of the literature. Mutat Res. 2009;681(2-3):299\u2013307. https:\/\/doi.org\/10.1016\/j.mrrev.2008.12.001.","journal-title":"Mutat Res"},{"issue":"12","key":"73_CR18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/hpb.12504","volume":"17","author":"M Potkonjak","year":"2015","unstructured":"Potkonjak M, Miura JT, Turaga KK, Johnston FM, Tsai S, Christians KK, et al. Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. HPB (Oxford). 2015;17(12):1119\u201323. https:\/\/doi.org\/10.1111\/hpb.12504.","journal-title":"HPB (Oxford)"},{"issue":"1","key":"73_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.21037\/jgo.2017.01.14","volume":"8","author":"E Borazanci","year":"2017","unstructured":"Borazanci E, Millis SZ, Kimbrough J, Doll N, Hoff DV, Ramanathan RK. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. J Gastrointest Oncol. 2017;8(1):164\u201372. https:\/\/doi.org\/10.21037\/jgo.2017.01.14.","journal-title":"J Gastrointest Oncol"},{"key":"73_CR20","doi-asserted-by":"publisher","unstructured":"Uemura S, Matsubayashi H, Kiyozumi Y, Uesaka K, Yamamoto Y, Sasaki K, et al. Pancreatic adenocarcinoma with a germline PTEN p.Arg234Gln mutation. Familial Cancer. 2017; https:\/\/doi.org\/10.1007\/s10689-017-0025-7.","DOI":"10.1007\/s10689-017-0025-7"},{"issue":"1","key":"73_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12885-017-3196-6","volume":"17","author":"ST Kim","year":"2017","unstructured":"Kim ST, Lee J, Park SH, Park JO, Park YS, Kang WK, et al. Prospective phase II trial of everolimus in PIK3CA amplification\/mutation and\/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer. 2017;17(1):211. https:\/\/doi.org\/10.1186\/s12885-017-3196-6.","journal-title":"BMC Cancer"},{"key":"73_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jbior.2014.07.002","volume":"56","author":"L Ciuffreda","year":"2014","unstructured":"Ciuffreda L, Falcone I, Incani UC, et al. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv Biol Regul. 2014;56:66\u201380. https:\/\/doi.org\/10.1016\/j.jbior.2014.07.002.","journal-title":"Adv Biol Regul"},{"issue":"23","key":"73_CR23","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2016.67.1412","volume":"34","author":"DP Sohal","year":"2016","unstructured":"Sohal DP, Mangu PB, Khorana AA, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(23):2784\u201396. https:\/\/doi.org\/10.1200\/JCO.2016.67.1412.","journal-title":"J Clin Oncol"},{"issue":"6","key":"73_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(16)00172-8.","journal-title":"Lancet Oncol"},{"issue":"3","key":"73_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5114\/wo.2015.52656","volume":"19","author":"M Ulker","year":"2015","unstructured":"Ulker M, Duman BB, Sahin B, Gumurdulu D. ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and\/or gemcitabine. Contemp Oncol (Pozn). 2015;19(3):207\u201313. https:\/\/doi.org\/10.5114\/wo.2015.52656.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"1","key":"73_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pan.2016.12.009","volume":"17","author":"C Baldini","year":"2017","unstructured":"Baldini C, Escande A, Bouche O, et al. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis. Pancreatology. 2017;17(1):146\u20139. https:\/\/doi.org\/10.1016\/j.pan.2016.12.009.","journal-title":"Pancreatology"},{"issue":"50","key":"73_CR27","doi-asserted-by":"publisher","first-page":"82953","DOI":"10.18632\/oncotarget.12761","volume":"7","author":"J Peron","year":"2016","unstructured":"Peron J, Roy P, Conroy T, et al. An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget. 2016;7(50):82953\u201360. https:\/\/doi.org\/10.18632\/oncotarget.12761.","journal-title":"Oncotarget"},{"key":"73_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2017.02.010","volume":"76","author":"JC Lee","year":"2017","unstructured":"Lee JC, Kim JW, Ahn S, Kim HW, Lee J, Kim YH, et al. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity. Eur J Cancer. 2017;76:125\u201333. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.010.","journal-title":"Eur J Cancer"},{"issue":"7625","key":"73_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature19823","volume":"538","author":"F Notta","year":"2016","unstructured":"Notta F, Chan-Seng-Yue M, Lemire M, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538(7625):378\u201382. https:\/\/doi.org\/10.1038\/nature19823.","journal-title":"Nature"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-018-0073-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-018-0073-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-018-0073-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:58:35Z","timestamp":1628600315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-018-0073-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,10]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6,15]]}},"alternative-id":["73"],"URL":"https:\/\/doi.org\/10.1007\/s12029-018-0073-8","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,10]]},"assertion":[{"value":"10 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Caris Life Sciences had no role in funding, design, implementation, or results, including interpretation and conclusions, of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}